Simple, sensitive and rapid determination of linifanib (ABT-869), a novel tyrosine kinase inhibitor in rat plasma by UHPLC-MS/MS

Chemistry Central Journal

Volumn 8, Issue 1, 2014, Pages

  Iqbal, Muzaffar ^a   Ezzeldin, Essam ^a   Wani, Tanveer A ^a   Khalil, Nasr Y ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

ABT 869; Linifanib; Pharmacokinetics; Rat plasma; UHPLC MS MS

Indexed keywords

EID: 84894362245     PISSN: None     EISSN: 1752153X     Source Type: Journal    
DOI: 10.1186/1752-153X-8-13     Document Type: Article

References (19)

1. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111(9):1287-1295. 10.1172/JCI200317929, 154450, 12727920.
2. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004, 18(2):338-340.
3. Dai Y, Hartandi K, Ji Z, Ahmed AA, Albert DH, Bauch JL, Bouska JJ, Bousquet PF, Cunha GA, Glaser KB, et al. Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem 2007, 50(7):1584-1597. 10.1021/jm061280h, 17343372.
4. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, Li J, Guo J, Bousquet PF, Ghoreishi-Haack NS, et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006, 5(4):995-1006. 10.1158/1535-7163.MCT-05-0410, 16648571.
5. Guo J, Marcotte PA, McCall JO, Dai Y, Pease LJ, Michaelides MR, Davidsen SK, Glaser KB. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther 2006, 5(4):1007-1013. 10.1158/1535-7163.MCT-05-0359, 16648572.
6. Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, et al. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011, 6(8):1418-1425. 10.1097/JTO.0b013e318220c93e, 21597387.
7. Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, McKeegan EM, Dowell B, Pedersen M, Qin Q, et al. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 2013, 119(2):380-387. 10.1002/cncr.27758, 22833179.
8. Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A, et al. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer 2011, 47(18):2706-2714. 10.1016/j.ejca.2011.09.002, 22078932.
9. Chiu YL, Carlson DM, Pradhan RS, Ricker JL. Exposure-response (safety) analysis to identify linifanib dose for a phase III study in patients with hepatocellular carcinoma. Clin Ther 2013, 35(11):1770-1777. 10.1016/j.clinthera.2013.09.002, 24094464.
10. Asahina H, Tamura Y, Nokihara H, Yamamoto N, Seki Y, Shibata T, Goto Y, Tanioka M, Yamada Y, Coates A, et al. An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 2012, 69(6):1477-1486. 10.1007/s00280-012-1846-6, 3362725, 22382879.
11. Wong CI, Koh TS, Soo R, Hartono S, Thng CH, McKeegan E, Yong WP, Chen CS, Lee SC, Wong J, et al. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 2009, 27(28):4718-4726. 10.1200/JCO.2008.21.7125, 19720910.
12. Rodila RC, Kim JC, Ji QC, El-Shourbagy TA. A high-throughput, fully automated liquid/liquid extraction liquid chromatography/mass spectrometry method for the quantitation of a new investigational drug ABT-869 and its metabolite A-849529 in human plasma samples. Rapid Commun Mass Spectrom 2006, 20(20):3067-3075. 10.1002/rcm.2703, 16969771.
13. Wu H, Zhang J, Norem K, El-Shourbagy TA. Simultaneous determination of a hydrophobic drug candidate and its metabolite in human plasma with salting-out assisted liquid/liquid extraction using a mass spectrometry friendly salt. J Pharm Biomed Anal 2008, 48(4):1243-1248. 10.1016/j.jpba.2008.09.002, 18926659.
14. Kumar A, Saini G, Nair A, Sharma R. UPLC: a preeminent technique in pharmaceutical analysis. Acta Pol Pharm 2012, 69(3):371-380.
15. Li F, Maguigad J, Pelzer M, Jiang X, Ji QC. A novel 'peak parking' strategy for ultra-performance liquid chromatography/tandem mass spectrometric detection for enhanced performance of bioanalytical assays. Rapid Commun Mass Spectrom 2008, 22(4):486-494. 10.1002/rcm.3389, 18215007.
16. Novakova L, Matysova L, Solich P. Advantages of application of UPLC in pharmaceutical analysis. Talanta 2006, 68(3):908-918. 10.1016/j.talanta.2005.06.035, 18970409.
17. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Guidance for industry on bioanalytical method validation. 2001, Rockville, MD: Department of Health and Human Services, [http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf], US Food and Drug Administration, Center for Drug Evaluation and Research (CDER).
18. European Medicines Agency Guideline on bioanalytical method validation, 2011. [http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf], European Medicines Agency.
19. Phillips GB, Dodge JT. Composition of phospholipids and of phospholipid fatty acids of human plasma. J Lipid Res 1967, 8(6):676-681.